OBSNZ Stock Overview
A biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ObsEva SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.018 |
| 52 Week High | CHF0.085 |
| 52 Week Low | CHF0.018 |
| Beta | 0.75 |
| 1 Month Change | 0% |
| 3 Month Change | -67.33% |
| 1 Year Change | -74.29% |
| 3 Year Change | n/a |
| 5 Year Change | -99.86% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| OBSNZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 0.5% |
| 1Y | -74.3% | -20.4% | 6.3% |
Return vs Industry: OBSNZ underperformed the UK Biotechs industry which returned -20.4% over the past year.
Return vs Market: OBSNZ underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
| OBSNZ volatility | |
|---|---|
| OBSNZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: OBSNZ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine OBSNZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 15 | Fabien de Ladonchamps | www.obseva.com |
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA Fundamentals Summary
| OBSNZ fundamental statistics | |
|---|---|
| Market cap | CHF140.61k |
| Earnings (TTM) | CHF7.22m |
| Revenue (TTM) | CHF17.88m |
0.0x
P/E Ratio0.0x
P/S RatioIs OBSNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBSNZ income statement (TTM) | |
|---|---|
| Revenue | US$19.64m |
| Cost of Revenue | US$10.71m |
| Gross Profit | US$8.93m |
| Other Expenses | US$1.01m |
| Earnings | US$7.92m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | 0.068 |
| Gross Margin | 45.46% |
| Net Profit Margin | 40.34% |
| Debt/Equity Ratio | 0% |
How did OBSNZ perform over the long term?
See historical performance and comparison